Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov-Dec;34(6):3483-3487.
doi: 10.21873/invivo.12188.

Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer

Misato Ogino  1   2   3 , Takaaki Fujii  4   2 , Yuko Nakazawa  1   2 , Toru Higuchi  5 , Yukio Koibuchi  3 , Tetsunari Oyama  6 , Jun Horiguchi  7 , Ken Shirabe  2
Affiliations

Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer

Misato Ogino et al. In Vivo. 2020 Nov-Dec.

Abstract

Background/aim: We evaluated the usefulness of topoisomerases (TOPs) expression as prognostic predictors in breast cancer.

Patients and methods: We retrospectively investigated sixty cases with primary breast cancer. We evaluated the tumor and non-tumor mRNA levels of TOP1 and TOP2α using quantitative reverse-transcription polymerase chain reaction. TOP1/TOP2α positivity was defined as the ratio of the mRNA expression of cancer/normal tissue of >1 for both TOP1 and TOP2α.

Results: TOP1 and TOP2α were markedly overexpressed in breast cancer tissues compared to normal breast tissues. Of the 60 cases, 46 (76.7%) were positive for TOP1/TOP2α. The relapse-free survival was relatively shorter for patients with positive TOP1/TOP2α. There was no recurrent disease among the 14 patients who were negative for TOP1/TOP2α, whereas four of the 46 TOP1/TOP2α-positive patients had disease recurrence.

Conclusion: Negative TOP1 or TOP2α expression may be useful for predicting better prognoses in breast cancer patients.

Keywords: Topoisomerase I; breast cancer; topoisomerase II alpha.

PubMed Disclaimer

Conflict of interest statement

The Authors declare that they have no competing interests in relation to this study.

Figures

Figure 1
Figure 1. The expression levels of TOP1 and TOP2α in cancer and noncancerous tissue are shown. (a) TOP1 and (b) TOP2α are markedly overexpressed in the cancer tissue compared to the non-cancerous tissue in cases with breast cancer
Figure 2
Figure 2. The disease-free survival (DFS) shown by the Kaplan–Meier curves is relatively but not significantly shorter for the cases with positive TOP1/TOP2α (p=0.276). Among the negative TOP1/TOP2α cases, there was no recurrent disease. The overall median follow-up period was 73.1 months (range=3.2-90.0 months).
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 counties. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. An X, Xu F, Luo R, Zheng Q, Lu J, Yang Y, Qin T, Yuan Z, Shi Y, Jiang W, Wang S. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. BMC Cancer. 2018;18(1):331. doi: 10.1186/s12885-018-4170-7. - DOI - PMC - PubMed
    1. Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 2013;10(9):494–506. doi: 10.1038/nrclinonc.2013.124. - DOI - PubMed
    1. Bush NG, Evans-Roberts K, Maxwell A. DNA topoisomerases. EcoSal Plus. 2015;6(2) doi: 10.1128/ecosalplus.ESP-0010-2014. - DOI - PMC - PubMed

MeSH terms

Substances